# Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

> **NCT06592170** · PHASE1,PHASE2 · RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 35 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Linperlisib combination with obinutuzumab

## Key facts

- **NCT ID:** NCT06592170
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2025-08-13
- **Final completion:** 2027-08-13
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592170, "Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06592170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*